Celgene Corporation's Revlimid Improves Survival in Blood Cancer Patients

Published: Jul 12, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in newly diagnosed blood cancer patients, potentially opening up the path for a wider use of the drug.

The company's shares were up 4 percent at $129.75 in premarket trade.

Help employers find you! Check out all the jobs and post your resume.

Back to news